Bausch Health Companies Inc. (NYSE:BHC) Shares Purchased by Compass Rose Asset Management LP

Compass Rose Asset Management LP increased its stake in shares of Bausch Health Companies Inc. (NYSE:BHC) by 366.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,100,000 shares of the company’s stock after purchasing an additional 1,650,000 shares during the quarter. Bausch Health Companies makes up approximately 6.9% of Compass Rose Asset Management LP’s holdings, making the stock its 6th largest holding. Compass Rose Asset Management LP’s holdings in Bausch Health Companies were worth $16,926,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Mountain Hill Investment Partners Corp. purchased a new position in Bausch Health Companies in the 4th quarter valued at about $56,000. Bank of Nova Scotia acquired a new stake in Bausch Health Companies during the fourth quarter worth about $83,000. One68 Global Capital LLC bought a new stake in shares of Bausch Health Companies in the 4th quarter worth approximately $90,000. Balyasny Asset Management L.P. bought a new position in shares of Bausch Health Companies during the fourth quarter worth about $97,000. Finally, Alpine Global Management LLC acquired a new stake in Bausch Health Companies in the 4th quarter valued at approximately $114,000. 78.65% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

BHC has been the subject of several recent research reports. Royal Bank of Canada increased their target price on shares of Bausch Health Companies from $8.50 to $10.00 and gave the company a “sector perform” rating in a research note on Friday, May 2nd. Jefferies Financial Group reiterated a “hold” rating and set a $8.00 price target (down previously from $12.00) on shares of Bausch Health Companies in a report on Thursday, February 6th. Finally, StockNews.com upgraded shares of Bausch Health Companies from a “hold” rating to a “buy” rating in a research note on Thursday, May 1st. One investment analyst has rated the stock with a sell rating, six have given a hold rating and one has given a buy rating to the company’s stock. According to MarketBeat.com, Bausch Health Companies currently has a consensus rating of “Hold” and a consensus price target of $7.42.

Bausch Health Companies Stock Down 3.4 %

BHC stock opened at $4.76 on Wednesday. Bausch Health Companies Inc. has a 12 month low of $3.96 and a 12 month high of $9.85. The firm has a market cap of $1.76 billion, a P/E ratio of -39.66, a P/E/G ratio of 0.37 and a beta of 0.34. The company’s 50-day moving average price is $5.94 and its two-hundred day moving average price is $7.17.

Bausch Health Companies (NYSE:BHC) last announced its quarterly earnings results on Wednesday, February 19th. The company reported $1.21 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.65 by ($0.44). Bausch Health Companies had a negative net margin of 0.48% and a negative return on equity of 577.82%. The business had revenue of $2.56 billion during the quarter, compared to analyst estimates of $2.51 billion. Equities analysts predict that Bausch Health Companies Inc. will post 4.41 EPS for the current year.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.